A Ras homologue member I (ARHI) is an imprinted tumor suppressor gene whose expression is frequently lost in pancreatic cancers. This small GTP-binding protein is a member of the Ras superfamily with significant homology to Ras. In contrast to the Ras oncogene, ARHI has been shown to have anti-proliferative effects, but the mechanisms by which it inhibits pancreatic cancer cell proliferation and induces cell cycle arrest remain unclear. By generating stable transfectants, ARHI was reexpressed in pancreatic cancer cells that had lost its expression. Flow cytometry analysis indicated that ARHI blocked cell cycle progression at the G 1 phase in pancreatic cancer cells. In ARHI transfectants, phosphorylated AKT protein expression decreased compared to that of vector transfectants. Reexpression of ARHI increased the expression of the cyclin-dependent kinase (CDK) inhibitor (CKI) p21 WAF1 , through the accumulation of p53 protein by the inhibition of PI-3K/AKT signaling. In addition, ARHI enhances expression of CKI p27 kip1 through the inhibition of PI-3K/AKT signaling. The expression of cyclins A and D1 decreased, while cyclin E was not affected under the same conditions. The activities of cyclin-dependent kinases 2 (CDK2) and 4 (CDK4) were reduced in ARHI transfectants. These results suggest that the PI-3K/AKT pathway plays a pivotal role in the pathogenesis of pancreatic cancer and ARHI exerts its growth-inhibitory effects through modulation of several key G 1 regulatory proteins, such as p21 WAF1 , p27 kip1 , CDK2, CDK4 and cyclins A and D1. ARHI represents a modulator of cancer cell proliferation and may play an important role in the development of pancreatic cancer.
Introduction
Pancreatic cancer is one of the most lethal cancers in the industrialized world and the sixth leading cause of cancerrelated death in China (1). The incidence of pancreatic cancer almost equals that of pancreatic cancer-related mortality, with fewer than 20% of patients surviving the first year and with only 3% surviving 5 years after the diagnosis (2) (3) (4) . This poor outcome motivates ongoing molecular research to understand tumor biology. A variety of regulatory mechanisms contribute to the development and growth of pancreatic cancer. The up-regulation of numerous oncogenic genes and the downregulation of tumor suppressor genes are responsible, in part, for the uncontrolled growth, survival and metastasis of pancreatic cancer cells during the development of this disease. The genetic abnormalities found in pancreatic cancer affect the mechanisms controlling G 1 to S cell cycle progression and cellular proliferation.
A Ras homologue member I (ARHI) is a maternally imprinted human tumor suppressor gene that encodes a 26-kDa small G protein with 50-60% amino acid homology to Rap and Ras. In ovarian and breast cancers, reexpression of ARHI inhibits cancer cell growth in vitro and in vivo, induces p21 WAF1 and down-regulates cyclin D1 promoter activity (5) . Recent studies showed that ARHI regulates autophagy and tumor dormancy in ovarian cancer (6) .
ARHI is expressed in normal pancreatic epithelial cells, but its expression is lost or down-regulated in pancreatic cancers (7) . The induction of this gene into pancreatic cancer cells that lack ARHI expression can block epidermal growth factor (EGF)-mediated signaling through RAS/mitogen-activated protein kinase, suppress STAT3 activity and induce apoptosis in pancreatic cancers (Hu and Lu, unpublished data). In this study, we further demonstrated that ARHI reexpression suppresses the proliferation of pancreatic cancer cells by modulating expression of cell cycle regulatory proteins.
Materials and methods
Cell culture and treatment. The human pancreatic carcinoma cell lines PANC-1 (anaplastic adenocarcinoma) and MiaPaCa-2 Cell cycle arrest analysis. Cells were plated at a density of 5x10 5 cells/plate in 60-mm tissue culture dishes. Cell cycle distribution was analyzed by flow cytometry. Briefly, pancreatic cancer cells and their stable pool transfectants were washed once with phosphate-buffered saline (PBS), harvested by trypsinization, collected and then resuspended in 300 μl of PBS and fixed with 5 ml of ice-cold 75% ethanol overnight. The cells were sedimented by centrifugation and resuspended in PBS containing 1 mg/ml each of glucose and RNaseA and incubated at room temperature for 30 min. Then, propidium iodide solution (1 mg/ml in distilled water) was added to each sample and incubated in the dark for an additional 30 min. The samples were analyzed via flow cytometry (Coulter Epics XL). Cell cycle analysis software was used to analyze the percentage of cells in the different phases of the cell cycle. Three different experiments were performed and the results are reported as means ± standard error.
Western blot analysis. Cells were washed twice with ice-cold PBS followed by lysis for 15 min in a buffer (20 mM sodium phosphate buffer, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, pH 7.4) supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF), sodium orthovanadate (1 mM, pH 7.4) and a mixture of phosphatase inhibitors. Cells were then scraped from the plates and the cell lysates were clarified by centrifugation for 15 min at 12,000 x g and 4˚C. The concentration of total protein was quantified using the Bicinchoninic Acid (BCA) method (Applygen). Total cell protein (50 μg) was separated via 10 or 12% SDS-PAGE, transferred to a PVDF membrane and blocked for 2 h at room temperature or overnight at 4˚C with 5% non-fat milk/TBS-Tween (TBS-T). Primary antibodies were diluted in blocking buffer and incubated overnight at 4˚C. To detect target proteins, we incubated the membranes with antibodies against: ARHI (from the laboratory of Dr Yu), p53 (Santa Cruz), p27
Kip1 (Santa Cruz), p21 WAF1 (Santa Cruz), cyclins A, D1 and E (Santa Cruz), CDK2, 4 (Santa Cruz), phospho-AKT polyclonal, AKT (Cell Signaling Technology, Beverly, MA) and actin (Santa Cruz), respectively. HRPconjugated secondary antibodies (Santa Cruz, anti-mouse and anti-rabbit) were diluted 1:2000 in TBS-T and incubated for 1 h at room temperature with gentle rocking. Proteins were visualized using ECL detection reagents (Applygen) and exposure to film (Kodak Biomax MR, Rochester, NY).
Results

ARHI reexpression inhibited growth of pancreatic cancer cells. Two pancreatic cancer cell lines (PANC-1, MiaPaCa-2)
were transfected with pIRES2-EGFP-ARHI. Stable transfectants were selected by G418. They exhibited clear expression of ARHI (Fig. 1) . Normal pancreas tissue was used as a positive control. The parental cell line and transfectants with vector did not have detectable ARHI expression and served as negative controls.
Previous studies have shown that ARHI inhibits the proliferation of ovarian and breast cancer cells (8) . Thus, we examined whether ARHI reexpression inhibits the proliferation of pancreatic cancer cells. As shown in Fig. 2 , stable transfectants of ARHI markedly inhibited anchorage-dependent growth of PANC-1 pancreatic cancer cells ( Fig. 2A) and MiaPaCa-2 pancreatic cancer cells (Fig. 2B) . The difference between ARHI transfectants vs. vector transfectants was statistically significant at 3, 4 and 5 days (P<0.05 or P<0.01).
Reexpression of ARHI causes cell cycle G 1 arrest. Since ARHI reexpression exerted marked effects on cellular proliferation as revealed by growth curvature assays (Fig. 2) , we analyzed the effects of this suppression on cell cycle progression. PANC-1 or MiaPaCa-2 cell lines, stably transfected with the ARHI constructs or with an empty vector, were examined by flow cytometric analysis and the percentages of cells in the S and G 1 phases were determined. As shown in Fig. 3 , cells reexpressing ARHI were arrested in the G 1 phase of the cell cycle. The fraction of cells in the G 1 phase increased from 56 to 75% (PANC-1) or 54 to 67% (MiaPaCa-2) compared with vector transfectants. No change in G 2 -M cells was observed. These results indicated that reexpression of ARHI strongly impacted cellular proliferation, which led to a reduction of S phase cells and cellular arrest in the G 1 phase.
Down-regulation of phosphorylated Akt (p-AKT) in ARHI
transfectants. The PI-3K/AKT pathway is an important regulatory pathway governing cell cycle progression and apoptotic response (9, 10) . We therefore investigated whether ARHI expression blocks the activation of PI-3K/AKT signaling in pancreatic cancer cells. As the activity of AKT is regulated by phosphorylation, we examined the level of p-AKT in PANC-1 or MiaPaCa-2 cells stably transfected with ARHI or vector at different time points. As shown in Fig. 4 , the level of p-AKT in ARHI transfectants was down-regulated compared with vector controls, but total levels of AKT protein remained unchanged. 
ARHI reexpression increased the expression of p21 WAF1 and p53 through the inhibition of the PI-3K/AKT signaling pathway.
Our present data show that ARHI down-regulated p-AKT expression. Previous studies have reported that the activation of PI-3K/AKT induces translocation of MDM2 from the cytoplasm to the nucleus, where it negatively regulates p53 (11) . To provide further evidence that AKT may be a crucial target of ARHI, we further investigated the effects of ARHI on another AKT target, p53, using Western blot analysis on PANC-1 pancreatic cancer cells. In agreement with the observed cell cycle arrest induced by ARHI, we observed up-regulation of p53 protein expression via the PI-3K/AKT pathway in ARHI transfectants, as compared with vector transfectants or untreated controls (Fig. 5) . Since p53 could induce G 1 cell cycle arrest through transcriptional activation of p21 WAF1 (12), we examined the effect of ARHI on the expression of p21 WAF1 . As expected, p21 WAF1 expression was clearly up-regulated in ARHI transfectants. To better understand the role of the PI-3K/AKT pathway in ARHIreactivation, we treated cells with PI-3K inhibitor LY294002. This specific inhibitor was able to block AKT activation, increasing p21 WAF1 expression via up-regulation of p53. ARHI expression displayed no change (Fig. 5) . These results suggest that the reexpression of ARHI increases p21 WAF1 , induces cell cycle G 1 arrest by up-regulation of p53 and blocks the PI-3K/ AKT pathway.
ARHI reexpression increased the expression of p27
kip1 . Many studies show that blocking the PI-3K/AKT signaling pathway modulates G 1 cell cycle progression and one critical target of this signaling process is the cyclin-dependent kinase (CDK) inhibitor (CKI) p27 kip1 (13) . Thus, we investigated whether ARHI up-regulates expression of p27 kip1 through the inhibition of PI-3K/AKT activation. As shown in Fig. 6,  p27 kip1 expression was increased in ARHI transfectants compared with vector transfectants and parental control cells. Additionally, PI-3K inhibitor LY294002 resulted in the 
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induction of p27 kip1 expression by regulating AKT activation. These results indicated that ARHI reactivation increases p27 kip1 expression by inactivating the PI-3K/AKT pathway.
The inhibitory effect of ARHI on the levels of cell cycle regulatory proteins. The cell cycle is regulated through the sequential activation and inactivation of CDKs that drive cell cycle progression through the phosphorylation and dephosphorylation of several regulatory proteins (14) . Additionally, progression from G 1 to S phase in cells is regulated by the accumulation of cyclins D1, E and A, which bind to and activate different CDK catalytic subunits. The activation of the CDK4-cyclin D1 complex is necessary for transition from early to mid-G 1 phase. Transition from mid-G 1 to S phase is regulated by activation of the CDK2-cyclin E complex. Progression through late G 1 to S phase also requires the presence of the CDK2-cyclin A complex (15) . Thus, we investigated whether ARHI modulates expression of cell cycle regulatory proteins (CDK2, CDK4, cyclin D1, cyclin A and cyclin E) involved in G 1 cell cycle arrest. In comparison with vector transfectants or parental control cells, the protein levels of cyclin A, cyclin D1, CDK2 and CDK4, but not cyclin E, were reduced by ARHI reexpression in pancreatic cancer cells (Fig. 7) .
Discussion
The existing data suggest that pancreatic oncogenesis is a multi-step process, during which oncogenes are activated and the function of tumor suppressor genes is lost (16) . ARHI is a tumor suppressor gene that is expressed by normal pancreatic cells (7) . Expression of ARHI is lost in a majority of pancreatic cancers (Yang et al, unpublished data) . Although the inhibition of cell proliferation is modulated by ARHI, the effects and mechanisms in pancreatic cancer have not been fully explored.
Past studies have shown that ARHI, an imprinted tumor suppressor gene, negatively regulates the PI-3K/AKT pathway in ovarian and breast cancers (17) . As reported previously, the PI-3K/AKT pathway plays a key role in the proliferation and survival of subsets of pancreatic epithelial cancer cells that are characterized by basal AKT activity (18, 19) . The activation of PI-3K/AKT in response to nerve growth factor, insulin-like growth factor-1, PDGF, interleukin-3 and the extracellular matrix promotes cell survival (20) (21) (22) . In this study, we demonstrate that ARHI reexpression suppresses the growth of pancreatic cancer cells, decreases AKT phosphorylation and arrests cell cycle progression in the G 1 phase. Hence, our data indicate that the PI-3K/AKT pathway is negatively regulated by ARHI (Fig. 4) ; this tumor suppressor might play an important role in cell proliferation of human pancreatic cancer cells.
To provide additional evidence for AKT as a crucial target of ARHI, we investigated the effects of ARHI on another AKT target, p53. AKT is known to promote cell survival through activation of the p53-binding protein MDM2, resulting in enhanced p53 degradation and negative regulation of the transcriptional functions of p53 (23) . The tumor suppressor gene p53 controls the G 1 and G 2 /M cell cycle checkpoints that mediate growth arrest (24) . Among the transcriptional targets of p53, the CDK inhibitor p21 WAF1 plays a key role in mediating G 1 arrest (25) . In this study, as expected, the findings showed that the levels of p53 and p21 WAF1 are increased due to ARHI reexpression (Fig. 5) . ARHI significantly reduced p-AKT protein expression and the PI-3K inhibitor LY294002 increased p53 and p21 WAF1 expression in ARHI transfectants, suggesting that ARHI is effective in promoting p53 and p21 WAF1 accumulation by inactivating PI-3K/AKT signaling in pancreatic cancer cells.
Based on previous findings in our lab, we further examined cell cycle distribution using flow cytometry analysis in ARHIor vector transfectants. As shown in Fig. 3 , we demonstrated that ARHI reexpression resulted in G 1 cell cycle arrest. Our data also showed elevated p27 kip1 expression due to ARHI reexpression through the suppression of the PI-3K/AKT signaling pathway (Fig. 6) . It is well known that G 1 -to-S cell cycle progression is controlled by several CDK complexes such as cyclin A-CDK2, cyclin E-CDK2 and cyclin D1-CDK4 (26); the activities of CDK complexes are dependent on the balance of cyclins and CKIs such as p27 kip1 and p21 WAF1 (27) . To determine whether ARHI-induced G 1 cell cycle arrest is due to the down-regulation of cyclins and CDKs, we analyzed the expression of these cell cycle regulators. The experiments indicated that ARHI reexpression downregulated cyclin A-CDK2 and cyclin D1-CDK4, but not cyclin E-CDK2 (Fig. 7) .
In conclusion, we show that expression of ARHI blocks PI-3K/AKT survival signaling in pancreatic cancer cells. ARHI reexpression upregulates p53, p21 WAF1 and p27 
